Hør Bruce Johnson, præsident for ASCO, fortælle om udviklingen af targeteret behandling og immunterapi

BestPractice | Juni 3, 2018 |

Professor i Medicin ved Harvard Medical School, dr. Bruce Johnson, fortæller i dette interview, hvordan targeteret behandling og immunterapi har ført til bedre resultater. Behovet for kemoterapi falder, og fremadrettet vil patienterne få en enklere behandling med betydelig bedre overlevelse.
#

Seneste nyheder

Potentiale as standard of care for patients with relapsed/refractory multiple myeloma
Potentiale as standard of care for patients with relapsed/refractory multiple myeloma
Click and hear Paul G. Richardson present the data for...
Promising activity for late-stage patients with relapses/refractory multiple myeloma
Promising activity for late-stage patients with relapses/refractory multiple myeloma
Despite recent advances in MM therapy, the disease remains incurable....